Stocksigma LogoStocksigma Logo

Symbiotec Pharmalab Reports Q2FY27 Revenue Surge and Profit Expansion

Symbiotec Pharmalab delivered strong Q2FY27 results, with consolidated revenue rising 43% YoY to Rs. 280 crs, EBITDA up 88% YoY to Rs

Symbiotec Pharmalab Reports Q2FY27 Revenue Surge and Profit Expansion

Symbiotec Pharmalab Ltd 路 Press Release 路 06 Nov 2026, 1:53 am

Symbiotec Pharmalab Reports Q2FY27 Revenue Surge and Profit Expansion Symbiotec Pharmalab delivered strong Q2FY27 results, with consolidated revenue rising 43% YoY to Rs. 280 crs, EBITDA up 88% YoY to Rs. 94 crs, and PAT jumping 169% YoY to Rs. 52 crs. Growth was aided by Rs. 53 crs in milestone revenue from Complex Injectables alongside steady 16% YoY growth in API revenue to Rs. 227 crs. For H1FY27, revenue reached Rs. 498 crs (up 25% YoY) with PAT at Rs. 66 crs. Net debt stood at ~Rs. 314 crs as of 30th Sep'26.

Original exchange filing (PDF)

More announcements from Symbiotec Pharmalab Ltd

All Symbiotec Pharmalab Ltd announcements